Investor Relations

Investor Overview

KemPharm uses its LAT platform technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.


Stock Quote
KMPH (Common Stock)
PriceChange% ChangeVolume
$3.85 - 0.12.53%11,857
Previous CloseToday's OpenIntraday HighIntraday Low
Exchange: NASDAQ (US Dollar)
10/28/16 11:23 a.m. ET
Refresh quote
Recent NewsMore >>
KemPharm Files IND for KP201/IR, a Single-Entity Benzhydrocodone HCl Immediate Release Abuse-Deterrent Prodrug for the Treatment of Acute Pain
KemPharm Announces Licensing Agreement with Acura Pharmaceuticals for Aversion® Abuse-Deterrent Technology
KemPharm Receives Clearance from FDA to Initiate Clinical Program for KP415, an Investigational Prodrug of D-Threo-Methylphenidate for the Treatment of ADHD
Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources